Cost

Real Monthly Cost of GLP-1 Medications in 2026

GLP-1 Companion · 8 min read

Most GLP-1 cost pages answer the wrong question. They quote the medication list price, then stop. But the buyer question is "what will this actually cost me every month once visits, labs, shipping, refills, dose changes, and coupons are included?"

My position: before you pay cash for any GLP-1 path, build the real monthly number. A treatment plan that looks affordable only because it ignores follow-up care or the coupon end date is not a plan.

2026 List Prices for Major GLP-1 Medications

These are the Wholesale Acquisition Cost (WAC) prices — the manufacturer's list price before any negotiations, insurance adjustments, or patient assistance. No patient pays these amounts if they have insurance or qualify for any assistance program.

• Ozempic (semaglutide 0.5, 1, or 2 mg weekly, for T2D): approximately $935/month
• Wegovy (semaglutide 2.4 mg weekly, for obesity/CVD): approximately $1,349/month
• Mounjaro (tirzepatide 2.5–15 mg weekly, for T2D): approximately $1,060/month
• Zepbound (tirzepatide 2.5–15 mg weekly, for obesity): approximately $1,060/month
• Rybelsus (oral semaglutide 3, 7, or 14 mg daily, for T2D): approximately $935/month
• Saxenda (liraglutide 3 mg daily, for obesity): approximately $1,400/month
• Orforglipron (oral GLP-1 RA, for T2D, approved 2025; obesity indication pending): list price approximately $400–$600/month

Out-of-Pocket Cost with Commercial Insurance

Most working-age Americans with employer-sponsored insurance or individual marketplace plans are in this category. Commercial insurance cost-sharing for GLP-1 medications depends on your plan's formulary tier, your deductible status, and whether a manufacturer savings card is stacked on top of insurance.

• Formulary Tier 2 (preferred brand): $50–$100 copay per month after deductible is met
• Formulary Tier 3 (non-preferred brand): $100–$200 per month after deductible
• With Novo Nordisk savings card stacked on top of Tier 2–3 insurance: $0–$25/month for Ozempic or Wegovy for eligible patients
• With Lilly savings card stacked on top of insurance: $25/month or less for Mounjaro or Zepbound
• During deductible phase (typically January–March for many plans): may pay full negotiated price (~$400–$700) until deductible is met
• High-deductible health plan (HDHP) before deductible: $400–$750/month during deductible phase; savings card often cannot be applied to HDHP deductible under IRS rules

Out-of-Pocket Cost with Medicare

Medicare Part D covers diabetes-indicated GLP-1s (Ozempic, Mounjaro, Rybelsus) but not obesity-indicated ones (Wegovy, Zepbound) unless the patient has established cardiovascular disease. Manufacturer savings cards are not available to Medicare beneficiaries.

• Ozempic or Mounjaro on Part D formulary (covered for T2D): $35–$100/month copay depending on plan tier and cost-sharing structure
• After $2,000 annual out-of-pocket cap (effective 2025 under Inflation Reduction Act): $0 for the remainder of the year for covered drugs
• Wegovy for cardiovascular disease indication (SELECT trial indication, 2024): covered under Part D for eligible Medicare beneficiaries; similar cost-sharing to other brand-name drugs
• Wegovy or Zepbound for obesity only (no CVD diagnosis): NOT covered by standard Part D; full list price applies (~$1,060–$1,349/month)
• Medicare beneficiaries with Low Income Subsidy (Extra Help): nominal copay of $4–$12 for covered generic/brand drugs

Out-of-Pocket Cost with Medicaid

Medicaid cost-sharing is low for covered medications, but coverage itself varies by state. For states that cover GLP-1s, cost-sharing is typically minimal.

• States covering GLP-1s (California, New York, Oregon, and others): $0–$4 copay per prescription for most Medicaid beneficiaries
• States not covering weight-management GLP-1s: T2D-indicated GLP-1s (Ozempic, Mounjaro) typically still covered at $0–$4 copay for eligible T2D patients
• States where coverage requires step therapy: cost may be $0 once approval is granted; the challenge is the approval process, not the copay

Manufacturer Savings Cards: What They Actually Save

Savings cards from Novo Nordisk and Eli Lilly are the most impactful cost-reduction tool available to commercially insured patients.

• Novo Nordisk savings card (Ozempic/Wegovy): commercially insured patients may pay as little as $25/month; the card covers up to $200/month in cost-sharing; re-enrollment typically required annually
• Lilly savings card (Mounjaro/Zepbound): commercially insured patients may pay as little as $25/month; Zepbound card offers up to $150/month in savings
• Savings cards are not available to patients with Medicare, Medicaid, Tricare, or other federal programs
• Savings card programs have monthly and annual caps; patients who use high doses that cost more may hit the cap
• Cards typically begin at savings card enrollment; there may be a brief processing period before the first fill

New Oral Options: Cost in 2026

The arrival of oral GLP-1 medications is creating more affordable options for some patients, particularly when combined with commercial insurance savings programs.

• Orforglipron (Eli Lilly, oral GLP-1 RA, T2D approved 2025): with commercial insurance and Lilly savings card, target copay is approximately $25–$150/month; list price approximately $400–$600/month before savings
• Rybelsus (oral semaglutide): same list price range as injectable Ozempic; comparable savings card availability; no cost advantage over injectable without savings program
• Generic semaglutide (oral): patent challenges and licensing agreements may bring generic oral semaglutide to market in late 2026–2027; estimated price $150–$300/month if generics launch as expected

Realistic Annual Cost Scenarios

Here is what a full year of GLP-1 therapy realistically costs across different insurance situations in 2026.

• Commercially insured with savings card (Wegovy or Zepbound at $25/month): ~$300/year — the best-case scenario for most working-age patients
• Commercially insured without savings card, Tier 3 formulary placement: $1,200–$2,400/year after deductible; up to $5,000+ if deductible is high
• Medicare Part D, T2D-indicated GLP-1 (Ozempic): $420–$1,200/year until $2,000 OOP cap; then $0
• Medicare, obesity-only indication without CVD: $12,720–$16,188/year at full list price — effectively unaffordable for most
• Medicaid in a coverage state: $0–$48/year in nominal copays
• Uninsured via manufacturer PAP (income qualifying): $0/year
• Uninsured, self-pay via LillyDirect Zepbound vials: $4,788–$6,588/year depending on dose
• Orforglipron with commercial savings card: approximately $300–$1,800/year depending on dose and savings card maximum

Cost should not be the reason a patient with clear clinical need cannot access GLP-1 therapy. The assistance infrastructure — savings cards, PAPs, state programs, and federally qualified health center access — exists to bridge the gap. But it requires active navigation. Your prescriber's office and a pharmacist are your best resources for identifying every option available to you.

The practical next step is to compare access routes before buying: insurance path, manufacturer assistance path, local clinician path, and telehealth partner path. /partners is useful when you want that comparison without starting from ads.

Sources

• Wilding et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM.
• Jastreboff et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. NEJM.